Zhixiang Jintai announced that GR2001 injection, a recombinant humanized monoclonal antibody for tetanus prevention independently developed by the company, has completed conference communication with the drug evaluation center of the National Medical Products Administration and officially initiated phase III clinical trials.
智翔金泰：启动GR2001注射液III期临床试验
Zhixiang Jintai: Launches Phase III Clinical Trial of GR2001 Injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.